Dr. Pishvaian Discusses Results of Entrectinib in Metastatic Pancreas Cancer
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.
The clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions was evaluated in a study presented at the 2018 Gastrointestinal Cancers Symposium. As response rates for this disease loom at 50%, investigators sought to target a distinct molecular subgroup that harbor actionable molecular alterations.
A 600 mg dose of entrectinib were given daily to 3 patients with pancreas cancer—2 with TRP-NTRK gene fusions, and 1 with SCL4-ROS1 gene fusion. Results showed that entrectinib was associated with response and prolonged disease control in all 3 patients. Additionally, all 3 patients had an improvement in quality of life while on the study, Pishvaian says.
